Category | n (%) |
---|---|
Group of IMD patients followed at the centre | |
Adult | 7/60 (11.7) |
Paediatric | 18/60 (30) |
Both | 35/60 (58.3) |
IMD types that affect the patients under the respondent’s carea | |
LSD | 51/60 (85) |
C-FAO | 46/60 (76.7) |
AOA | 45/60 (75) |
PM-MD | 43/60 (71.7) |
CDG | 38/60 (63.3) |
NOMS | 25/60 (41.7) |
PD | 25/60 (41.7) |
Since the beginning of the pandemic, have you had any paediatric IMD patients confirmed positive for SARS-CoV-2 by either antigen, molecular or antibody testing? | |
Yes | 34/60 (56.7) |
No | 22/60 (36.7) |
Do not know | 4/60 (6.7) |
No answer | 0/60 (0) |
Among your paediatric patients who tested positive for COVID-19, which IMD types were mainly affected?a | |
AOA | 19/34 (55.9) |
LSD | 13/34 (38.2) |
C-FAO | 11/34 (32.4) |
CDG | 5/34 (14.7) |
PM-MD | 2/34 (5.9) |
PD | 0/34 (0) |
NOMS | 0/34 (0) |
No answer | 2/34 (5.9) |
Since the beginning of the pandemic, have you had any adult IMD patients confirmed positive for SARS-CoV-2 by either antigen, molecular or antibody testing? | |
Yes | 26/60 (43.3) |
No | 19/60 (31.7) |
Do not know | 13/60 (21.7) |
No answer | 2/60 (3.3) |
Among your adult patients who tested positive for COVID-19, which IMD types were mainly affected?a | |
LSD | 18/26 (69.2) |
AOA | 12/26 (46.2) |
C-FAO | 9/26 (34.6) |
PM-MD | 4/26 (15.4) |
PD | 1/26 (3.9) |
CDG | 1/26 (3.9) |
NOMS | 1/26 (3.9) |
No answer | 0/26 (0) |